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Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is Conclusions: NAFLD is the commonest cause of incidental LFT
a common cause of abnormal LFTs in primary care, but
there are no data deﬁning its contribution nor reporting the range
of NAFLD severity in this setting. This study seeks to calculate the
range of disease severity of NAFLD in a primary care setting.
Methods: Adult patients with incidental abnormal LFTs, in the
absence of a previous history, or current symptoms/signs of liver
disease were prospectively recruited from eight primary care
practices in Birmingham. NAFLD was diagnosed as fatty liver on
ultrasound, negative serological liver aetiology screen, and alco-
hol consumption 630 and 620 g/day in males and females,
respectively. The NAFLD Fibrosis Score (NFS) was calculated to
determine the presence or absence of advanced liver ﬁbrosis in
subjects identiﬁed with NAFLD.
Results: Data from 1118 adult patients were analysed. The cause
of abnormal LFTs was identiﬁed in 55% (614/1118) of subjects,
with NAFLD (26.4%; 295/1118) and alcohol excess (25.3%; 282/
1118) accounting for the majority. A high NFS (>0.676) suggesting
the presence of advanced liver ﬁbrosis was found in 7.6% of NAFLD
subjects, whereas 57.2% of NAFLD patients had a low NFS
(<1.455) allowing advanced ﬁbrosis to be conﬁdently excluded.Journal of Hepatology 20
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MW, Mann, Whitney U test; IQR, interquartile range.abnormalities in primary care (26.4%), of whom 7.6% have
advanced ﬁbrosis as calculated by the NFS. This study is the
ﬁrst of its kind to highlight the burden of NAFLD in primary
care and provide data on disease severity in this setting.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
The incidence of liver disease is rising throughout the world
and now accounts for 1.5% of deaths in the UK (www.statis-
tics.gov.uk). In parallel with this, there has been a year on year
rise in the number of liver function test (LFT) proﬁles carried
out in UK primary care practices (from 62,300 to 109,619/year
between 2002 and 2010; University Hospital Birmingham
(UHB) laboratories audit, UK). Primary care practitioners (PCPs)
are thus commonly faced with the scenario of abnormal liver
function tests (ALFT) in patients in whom there are no clinical
risks, signs or symptoms of liver disease. Non-alcoholic fatty
liver disease (NAFLD) is now recognized as the most common
cause of hepatic dysfunction in general population [1,2], how-
ever, this is yet to be conﬁrmed in primary care practice. Fur-
thermore, because of the indolent asymptomatic nature of
NAFLD, identifying those with advanced disease in whom spe-
ciﬁc interventions may be required remains a clinical challenge
in primary care.
The prevalence of NAFLD has risen markedly to 14–34% of
the general-population in Europe [2,3], Asia [4], and America
[5] in recent years. Whilst patients with simple NAFLD are
believed to have benign disease, there is now clear evidence
that those who have progressed to non-alcoholic steatohepati-
tis (NASH) and ﬁbrosis are at a much higher risk of developing
hepatocellular carcinoma (HCC), liver failure, and death [6,7].
The majority of data describing the severity of liver ﬁbrosis
in NAFLD arises from selected populations in secondary referral
centres [7–13]. In a large UK prospective study, Skelly et al.12 vol. 56 j 234–240
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demonstrated that 18% (23/120) of biopsy conﬁrmed NASH
patients had signiﬁcant ﬁbrosis after presenting to their
secondary care centre with unexplained ALFTs [12]. This and
other such studies [9,10] included patients in whom the deci-
sion to refer had been made on clinical grounds by PCPs/con-
sultant colleagues and were then rigorously screened in liver
clinics for other disease aetiologies prior to proceeding to liver
biopsy. These studies are, therefore, inﬂuenced by ascertain-
ment bias and may overestimate the severity of NAFLD emerg-
ing from primary care.
It is currently expected with the alarming growth of obesity
and type 2 diabetes that the burden of NAFLD on primary care
and liver services will continue to rise in the UK [14]. To date,
no studies have determined the underlying disease severity of
NAFLD in primary care. PCPs remain at the forefront of identi-
fying the patients with advanced NAFLD who require further
evaluation, closer surveillance for complications (and interven-
tions where appropriate) and stricter lifestyle modiﬁcations. By
investigating a large UK primary care sample of patients
with incidental ALFTs and absent clinical features of liver dis-
ease, this study is the ﬁrst of its kind to determine the pres-
ence and disease severity of silent NAFLD in a primary care
setting.Materials and methods
Study population
Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS) is a
prospective study of patients with an incidental ﬁnding of ALFTs in primary
care funded by NIHR Health Technology Assessment program (http://
www.hta.ac.uk/1459). Patients were prospectively recruited from primary
care practices from Birmingham and Lambeth areas, between 2006 and
2008. The primary aim of the BALLETS study was to assess the clinical
utility of ALFTs in patients in whom liver disease was not suspected clinically
by the PCP. St. Thomas’ Hospital Research Ethics Committee approved
the study and all study participants gave signed informed consent to be
included.
This current cross-sectional sub-study utilizes baseline data from patients
enrolled in the BALLETS study from the eight primary care practices within
the Birmingham region only. PCPs from participating practices reviewed all
new incidental ALFT results arising from their practices in patients in whom
the clinical suspicion of underlying liver disease was absent or low. Patients
over eighteen years old were eligible for the sub-study if one or more LFT ana-
lyte was abnormal and there was no previous documented history of liver dis-
ease, intravenous drug use and/or alcohol-related health problems. Current
signs or symptoms suggestive of liver disease, pregnancy, and a diagnosis of
disseminated malignancy were also considered exclusion criteria. Eligible
patients who consented for the study completed an interview during which
current illnesses, past medical history, alcohol consumption, socio-demographic
details, and drug history were recorded. Reasons for the original LFTs being
ordered by the PCP were also recorded. Patient’s height, weight, and waist cir-
cumference were measured. All patients had a repeat set of LFTs and a full
serological liver aetiology screen (viral, genetic and autoimmune) at the study
visit. An abdominal ultrasound scan (USS) was obtained in the fasted state
using an ultrasound machine (TITAN Sonosite) operated by one of ﬁve (10–
30 years experience) abdominal sonographers. All scans were recorded on tape
and 50 of these were selected at random and validated by a consultant radi-
ologist (Olliff S).
PCPs were sent a consolidated report of all study investigations. The study
team recommended to the PCP the need for a hepatology referral to the tertiary
liver clinic (UHB) in the event of one of the following: (1) positive serological liver
aetiology screen; (2) sonographic features of cirrhosis (coarse echotexture, irreg-
ular contour), space occupying liver lesion(s) or biliary duct dilatation. All liver
clinic letters were retrospectively reviewed (until 1st May 2010) to identify which
of these diagnoses were followed up and conﬁrmed by a liver specialist
(Supplementary Table 1).Journal of Hepatology 201Data deﬁnitions
The sub-study LFT proﬁle consisted of alanine aminotransferase (ALT), aspartate
aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyltransferase
(GGT), total bilirubin, and albumin measurements. Seven of the eight Birmingham
practices sent samples to a central laboratory at UHB, whilst the remaining prac-
tice sent samples to the laboratory of Russells Hall Hospital. Initial LFTs requested
by the PCP were used as a criterion for study entry, whereas the repeat LFTs
undertaken at the study visit were performed to increase the likelihood of a com-
plete panel of the six analytes listed and to avoid analyte selection bias that may
have occurred in the primary care practice. The analytes were classiﬁed as normal
or abnormal based on reference ranges speciﬁc to each of the two individual
laboratories, which are compliant with International Quality Control Standards
(Supplementary Table 2). The full blood liver aetiology screen consisted of viral
hepatitis B (HBV) surface antigen, viral hepatitis C (HCV) antibody, caeruloplas-
min, iron and transferrin saturation, alpha-1 anti-tryspin, anti-smooth muscle,
and anti-mitochondrial antibodies.
Body mass index (BMI) was deﬁned as weight in kilograms divided by the
square of the height in metres (kg/m2). Obesity was deﬁned as BMI P30 kg/m2.
Alcohol intake was reported as standard units (1 U = 10 g alcohol) of alcohol
consumed on average per week in the 6 months prior to recruitment. Mild
(female 1–7 U, male 1–11 U/week) and moderate (female 8–14 U, male 12–
21 U/week) alcohol consumption were deﬁned as drinking within the current
UK health guidelines (female 614, male 621 U/week; British Medical Association
1995). At-risk alcohol consumption was deﬁned as exceeding these guidelines.
For the purposes of this sub-study, type 2 diabetes was deﬁned in patients
with a documented history of the disease or a recorded drug history of anti-
diabetic medication. Hypertension was deﬁned as a past medical history of the
disease or a current recorded drug history of two or more anti-hypertensive
medications.
The diagnosis of NAFLD was based on the following criteria: (1) sonographic
diagnosis of fatty liver, deﬁned as diffusely increased liver echogenicity (>right
renal parenchyma) with vascular blurring; (2) a negative history of alcohol
consumption exceeding current UK health guidelines; and (3) exclusion of liver
disease of other aetiology including drug-induced, autoimmune, viral hepatitis,
cholestatic, metabolic and genetic liver disease.NAFLD Fibrosis Score
The NAFLD Fibrosis Score (NFS) [8] is a simple non-invasive scoring system
designed to identify or exclude advanced ﬁbrosis (classiﬁed as Kleiner stages F3
and F4 [15]) in patients with an established diagnosis of NAFLD on imaging.
The NFS was developed and validated by Angulo et al. [8] in over 700 liver
biopsy-proven patients with NAFLD and is routinely used in liver clinics to select
those at risk of disease progression and HCC. The NFS utilizes a number of simple
clinical and laboratory independent predictors of advanced liver ﬁbrosis:
NFS = 1.675 + 0.037  age (years) + 0.094  BMI (kg/m2) + 1.13  IFG/diabetes
(yes = 1, no = 0) + 0.99  AST/ALT ratio  0.013  platelet count (109/
L)  0.66  albumin (g/dl) [8]. The low cut-off score (<1.455) has a negative pre-
dictive value (NPV) of 88–93% and the high cut-off score (>+0.676) has a positive
predictive value (PPV) of 79–90% for the presence of advanced ﬁbrosis in NAFLD
in secondary care populations [8,16]. The NFS was calculated retrospectively
using the web-based calculator (http://NAFLDscore.com).
As the original BALLETS study protocol did not incorporate a platelet count,
retrospective data collection of the electronic haematology laboratory archive
at the UHB enabled platelet counts within 6 months of patient enrolment to be
recorded. To avoid false positive or false negative NFS, the scoring system was
not applied to participants with a past medical history of platelet disorders, on
myelosuppressive medications or an active systemic-inﬂammatory disease.Statistical analysis
Descriptive statistics were applied to characterize the whole study cohort and
the identiﬁed NAFLD group. Continuous clinical and laboratory variables are
reported as medians and interquartile ranges (IQR) as all variables had a
non-parametric distribution on D’Agostino and Pearson Omnibus Normality test-
ing (GraphPad Prism 5). Categorical variables are reported as numbers and per-
centages. Due to a variation in normal reference ranges between the two
laboratories utilized for the initial PCP LFT samples, blood results from Russell
Hall Hospital (n = 89 patients) were standardised to the central laboratory refer-
ence ranges at UHB using the proportion of the upper (or lower with albumin)
limit of normal.2 vol. 56 j 234–240 235
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Results
A total of 1118 primary care patients were included. The PCPs
reason for the LFT requests are shown in Table 1. The majority
(38%; 424/1118) of these resulted from routine chronic disease
check-ups. In 4.5% (50/1118) of cases no reason was recorded.
Liver aetiology screen and ultrasound were successfully com-
pleted in 98% (1101/1118) of patients at the study visit. ThereTable 1. The 10 most commonly recorded reasons for why the LFT’s were
undertaken by the PCP. Values are percentages (numbers). Percentages include
all values (n = 1118). Other reasons accounted for 20.9% (234).
Documented reason Percentage (n)
Diabetes review 18.0 (201)
15.2 (171)Non-specific routine bloods
(excluding liver-specific)
Medications review (non-specific)
Hypertensive disease review 11.4 (128)
Gastrointestinal symptoms 10.0 (112)
Generalised fatigue or tiredness 6.2 (69)
Cardiovascular disease review 4.7 (53)
4.5 (50)
Hyperlipidaemia disease review 3.8 (42)
Neurological symptoms (inc. confusion) 2.7 (31)
Musculoskeletal symptoms (i.e. joint pain) 2.4 (27)
Table 2. Demographics and characteristics of study participants (left) and those ide
Characteristics Total (n = 1118)
Median (IQR) age (years) 60 (48-70)
Gender
Male
Female
56 (628)
44 (490)
Ethnicity (%)
White
African-Caribbean
Asian/Arabic
Mixed/other
Unknown
83.9 (938)
3.9 (44)
8.1 (90)
1.3 (15)
2.8 (31)
Alcohol consumption cut-offs
Abstinence
Mild
Moderate
At-risk
42.5 (475)
20.8 (232)
10.5 (117)
26.3 (294)
Metabolic Phenotypes
Type 2 diabetes 23.5 (263)
Hypertensive Disease 43.2 (483)
Obesity 40.7 (455)
Median (IQR) measured BMI (Kg/m2) 28.7 (25.3-33.1)
Median (IQR) waist circumference (cm)
Male
Female
103 (95-112)
96 (85-109)
Values are percentages (numbers) unless stated otherwise. Percentages do not include
236 Journal of Hepatology 201was a 100% agreement between the consultant radiologist and
the study sonographers in reporting the presence or absence of
fatty liver on USS in 50 randomly selected cases. Study demo-
graphics and characteristics are summarised in Table 2.
Causes of ALFTs
The cause of ALFTs was identiﬁed in 54.9% (614/1118) of cases
(Table 3). Detailed testing for viral, genetic, and autoimmune
causes yielded 33 diagnoses (3.0%). NAFLD was identiﬁed as the
commonest cause of ALFTS accounting for 26.4% of all cases,
exceeding alcohol excess (25.3%). The demographics and meta-
bolic parameters of the identiﬁed NAFLD group are summarised
in Table 2. There were no reported cases of cirrhotic appearances
or ascites on USS in the NAFLD cohort. Splenomegaly (P13 cm)
was reported in 7.8% (23/295) of NAFLD cases, albeit only mar-
ginally enlarged (median 13.6 cm, IQR 13.2–14.0). Two or more
ALFT analytes were present in 40.7% of NAFLD subjects (120/
295), with the remainder having a single analyte abnormality
(59.3%; 175/295) on PCP sampling. GGT was the most common
LFT abnormality in the NAFLD cohort (75.7%; 197/260), with a
median value 1.6 times the upper limit of normal (Fig. 1). Median
time difference between bloods ordered by the PCP and the study
visit was 30 days (IQR 18–51).
At-risk alcohol consumption was reported in 25.3% (282/
1118). The majority of at-risk alcohol consumers were male
(73.4%; 126/282) and drank a signiﬁcant greater amount of alco-
hol (units per week) than females (median 42 (IQR 30–56) versus
29 (IQR 21–46), Mann–Whitney U test = p< 0.001). An echo-
bright fatty liver was identiﬁed with USS in 44.7% (126/282) ofntiﬁed with NAFLD (right).
NAFLD (n = 295)
58 (49-66.7)
56.6 (167)
43.4 (128)
84.1 (248)
2.0 (6)
9.8 (29)
1.7 (5)
2.4 (7)
56.9 (168)
28.1 (83)
14.9 (44)
 0 (0)
38.6 (116)
45.4 (134)
60.3 (179)
31.5 (28.1-35.8)
107 (101-115)
107 (96-115)
missing values.
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Table 3. Causes of incidental ALFT. Percentages include all values (total n = 1118). LFT analyte (inclusive of normal and abnormal values) from study visit are expressed
as medians (IQR).
Cause Percentage (n) GGT [U/L] ALT [U/L] AST [U/L] ALP [U/L) Bili [µmol/L] Alb [g/L]
NAFLD 26.4 (295) 59 (41-88) 38 (27-54) 30 (23-40) 206 (167-266) 9 (6-12) 45 (43-47)
At-risk alcohol intake
Non-Fatty liver
Fatty liver
14.0 (156)
11.3 (126)
69 (46-115)
81 (52-148)
30 (22-44)
46 (33-65)
28 (22-35)
36 (28-49)
190 (159-238) 
178 (150-218)
10 (7-13)
9 (8-13)
46 (44-48)
47 (45-49)
PBC 0.81 (9) 99 (45-186) 15 (20-31) 27 (25-36) 396 (337-463) 7 (6-13) 43 (42-45)
HBV 0.72 (8) 53 (32-418) 92 (49-156) 62 (26-97) 184 (147-242) 8 (5-15) 46 (43-52)
Haemochromatosis
Homozygote 
[C282Y or H63D]
Comp. heterozygote 
[C282Y + H63D]
0.54 (6)
0.36 (4)
73 (31-166)
56 (25-458)
59 (43-79)
51 (54-149)
39 (32-56)
25 (42-238)
202 (158-382)
121 (75-135)
8 (5-23)
12 (5-21)
46 (45-48)
51 (45-53)
Other (inc. cancer,
drug, abscess)
0.36 (4) 85 (27-179) 29 (17-58) 31 (18-44) 273 (191-368) 12 (7-18) 44 (39-48)
HCV* 0.17 (2) x (34, 452) x (151, -) x (101, 70) x (514, 214) x (8, 8) x (48, 47)
PSC* 0.17 (2) x (-, 600) x (51, 212) x (33, 124) x (176, 990) x (12, 10) x (47, 46)
A1AD* 0.17 (2) x (59, 62) x (41, 50) x (24, 25) x (161, 138) x (11, 12) x (48, 50)
Unexplained group 45.1 (504) 56 (33-91) 26 (19-38) 26 (22-33) 202 (162-274) 9 (6-13) 45 (43-47)
⁄True analyte values are listed in brackets if n <4. (x) represents missing value or median.
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Fig. 1. Frequency and extent of LFT abnormalities in the identiﬁed NAFLD
cohort. Percentages do not include missing values. The extent of the LFT
abnormality is expressed as a proportion of the upper (or lower⁄) limit of normal
(median values reported above bars).
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Fig. 2. NAFLD Fibrosis Scores in patients that met the diagnostic criteria for
NAFLD. Percentages do not include missing values.
JOURNAL OF HEPATOLOGYsubjects who consumed at-risk levels of alcohol. The majority of
excess drinkers (87%; 110/126) had a BMI greater than 25 kg/m2.
USS identiﬁed cirrhotic appearances in two cases (one with
splenomegaly; 15 cm) of at-risk alcohol consumption. The diag-
nosis of compensated alcohol-induced cirrhosis was conﬁrmed
by tertiary liver specialists.
No cause for LFT abnormality was identiﬁed in the remainder
of study subjects (45.1%; 504/1118). Liver disease could not be
ruled out in 8.1% (41/504) of unexplained cases due to incom-
plete liver aetiology screen (n = 10), USS (n = 7) and absence ofJournal of Hepatology 201referral to liver specialist/patient non-attendance after a positive
liver aetiology screen test (bile duct dilatation, n = 1; transferrin
saturation >50%, n = 6; low caeruloplasmin, n = 17). LFTs norma-
lised between PCP and study visit sampling (median 30 days, IQR
18–63) in 19.9% (92/463) of unexplained cases with a completed
USS and liver aetiology screen. Metabolic risk factors in the unex-
plained ALFT group included obesity (30.5%, 154/504), diabetes
(19.0%, 96/504) and hypertension (41.3%, 208/504). Of note,
18.5% (95/504) had co-existing obesity with either diabetes
and/or hypertensive disease.
Disease severity in the cohort of patients with NAFLD
To calculate the severity of NAFLD in this cohort we retrospec-
tively applied the NFS. The score was calculated in 236 of the2 vol. 56 j 234–240 237
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295 patients who met the diagnostic criteria for NAFLD (Fig. 2).
The NFS was not calculated in the remaining 59 patients with
NAFLD as a result of incomplete records of blood platelets
(n = 50), BMI (n = 5) and AST/ALT ratio (n = 4). A high NFS
(>+0.676) was found in 7.6% (18/236) of patients with NAFLD,
suggesting the presence of underlying advanced liver ﬁbrosis
(Stages F3/F4 on Kleiner classiﬁcation [15]). Advanced ﬁbrosis
was predicted to be absent in the majority of NAFLD subjects
with a low NFS (<1.455) being calculated in 57.2% (135/236).
The presence of advanced ﬁbrosis, however, could not be conﬁ-
dently excluded in 35.2% (83/236) of the NAFLD patients who
scored an indeterminate value with the NFS (1.455 to +0.676).
Discussion
This large primary care study highlights that NAFLD accounts for
over 25% of incidental ALFTs in primary care consultations, in
which the consulting PCP’s suspicion of underlying liver disease
is low or absent. In contrast, only 3.0% of all study patients had
a speciﬁc viral (HBV/HCV), genetic, or autoimmune disease iden-
tiﬁed on thorough study testing. Application of a simple, non-
invasive scoring system suggests that undetected advanced liver
ﬁbrosis is present in 7.6% and absent in 57.2% of the NAFLD
patients. Incidental ALFTs were most commonly encountered
during routine chronic disease reviews (38% cases), including dia-
betes, hypertension, and cardiovascular disease. This study is the
ﬁrst of its kind to report the severity of NAFLD in patients with
incidental ALFTs in primary care.
Our study evaluated a PCP-based population with ALFTs
rather than a population volunteered from the general commu-
nity. Nonetheless, the frequency of NAFLD (26%) identiﬁed in
our study is within the wide range (14–34%) previously reported
in general population studies carried out in Italy [2], Spain [3],
Asia [4], and America [5]. The variation in reported frequencies
may be inﬂuenced by ethnic diversity [5,17] and differences in
study methodologies. These include variable alcohol thresholds
that deﬁne NAFLD, lack of consistency in screening for other dis-
ease aetiologies, and variation in risk stratiﬁcation for liver dis-
ease at study enrolment. All the studies nevertheless conﬁrm
the strong association between NAFLD and components of the
metabolic syndrome [4,18], the prevalence of which has
increased rapidly worldwide [14]. The high proportion of patients
with diabetes (38.6%), obesity (60.3%) and hypertension (45.4%)
in the NAFLD group in our study is in keeping with population-
based studies [2].
The suspected proportion of advanced ﬁbrosis within our
NAFLD cohort is 7.6%. Additionally, from experiences in hospital
care [8,16,19], we predict that a sub-set of the 35.2% of patients
with an indeterminate NFSmay also have advanced ﬁbrosis. There
are currently no data on the severity of NAFLD in primary care. The
most relevant studies that best reﬂect low-risk populations are
restricted to biopsy ﬁndings in living-related liver donors, in
which the prevalence of NASH (± ﬁbrosis) ranges from 1.1% in
Japan [20] to 18.5% in the US [21]. The latter ﬁgure is likely to be
an overestimate due to the lack of detail on alcohol consumption
and full liver aetiology screening in liver donors. Secondary/
tertiary centre studies of variable size (range118–733) and
Caucasian predominance have reported that 11–27% of patients
with biopsy-proven NAFLD and elevated aminotransferases have238 Journal of Hepatology 201advanced (stages 3/4) ﬁbrosis [7,13,19,22,23]. The higher rates of
advanced ﬁbrosis reported in these liver specialist centres are
likely to be due to referral/sampling bias.
Our study has several unique strengths. First, this is the largest
prospective cohort of primary care patients with clinically unsus-
pected liver disease and incidental ALFTs to be reported. Second,
this is the ﬁrst study to apply the non-invasive NFS to identify
patients with advanced NAFLD ﬁbrosis in primary care that are
most in need of intensive lifestyle modiﬁcations and surveillance
for liver-related complications (e.g. HCC detection). Third, the
detailed assessment of the liver aetiology screen (alcohol/drug
data, serology, genetics, and USS imaging) undertaken and high
completion rate (98%) has meant that a cause for ALFT was identi-
ﬁed in the majority of cases (55%). Previous large-scale popula-
tion-based retrospective analyses of ALFTs have been limited by
the absence of USS [1] and the lack of information on alcohol
andmeasured anthropometry [24] to accurately describe the pres-
ence of NAFLD. The high rate of liver disease identiﬁcation in our
patient sample that PCPs perceived as a low risk group may also
be explained by the fact that GGT, which has the highest reported
sensitivity for liver disease above other LFTS [24], was the com-
monest LFT abnormality. The ﬁnding of an elevated GGT in more
than 70% of the NAFLD group as opposed to ALT (51.0%) and AST
(26.2%) has not previously been reported in adult NAFLD patients.
This ﬁnding has also been reported in paediatric NAFLD [25].
One limitation of this study is that the application of the NFS
was validated against liver biopsy in NAFLD patients attending
hospital [8,16,19], and so it is possible that the severity of NAFLD
may be over-estimated in our primary care cohort. However, our
NAFLD cohort has very similar patient characteristics (Caucasian,
obese, middle-aged, with ALFTs) to those reported by Angulo
et al. [8], and in many countries the distinction between primary
and secondary care is not as clear. The NFS was chosen over other
non-invasive systems [23,26,27] that detect advanced ﬁbrosis for
the purpose of our study as it is an easily applicable tool (web-
based calculator) that has the best reported PPV in secondary
care [16], entails minimal extra cost to GPs (i.e. platelet sampling)
and incorporates blood and clinical parameters that are routinely
available in primary care. We were not able to validate the NFS
against other non-invasive modalities [26–28] as these had not
been developed nor sufﬁciently studied by the time our study
had started. Moreover, there are issues about how to validate
such modalities in primary care, as it is unlikely and also uneth-
ical that liver biopsies would ever be performed in such a large
sample of patients or in this setting. NFS is limited to predicting
the presence or absence of advanced ﬁbrosis only, and does not
distinguish between benign steatosis alone (non-NASH) and the
inﬂammatory process of steatohepatitis (NASH). Previous studies
have highlighted that NAFLD patients with NASH (independent of
ﬁbrosis) have a higher risk of death from liver disease and to a
greater extent cardiovascular disease than those with non-NASH
[7,29]. At present, however, non-invasive tools do not exist in pri-
mary care to identify individuals with NASH ± early ﬁbrosis.
Despite a thorough non-invasive aetiology screen and detailed
alcohol history, 45% had unexplained ALFTs in our cohort. How-
ever, as we targeted the more problematic patients in primary
care that have incidental ALFTs in the absence of a clinical suspi-
cion of underlying liver disease, this is not a surprise. Further-
more, unlike previous general population studies [1,2] that only2 vol. 56 j 234–240
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utilised ALT, AST, and/or GGT, our study recruited patients with a
wider spectrum of LFT analytes to reﬂect common practice in pri-
mary care. It is, therefore, possible that some of the unexplained
ALFTs represent transient (viral) illness, Gilbert’s syndrome,
under (self-) reported use of alcohol/over-counter medications
or non-liver related disease (i.e. bone, muscle) [1]. The ﬁnding
that 20% of the unexplained group normalised LFTs within an
average of 30 days of re-testing supports this hypothesis.
Although USS is the most readily available imaging tool available
in primary care, the fact that 18% of the ‘unexplained’ group had
co-existing obesity with diabetes and/or hypertension raises the
possibility that reliance on ultrasound alone will miss a propor-
tion of cases of NAFLD. The difﬁculty in detecting the presence
of fatty liver with USS is well reported in the morbidly obese
and when the degree of fat inﬁltration is less than 33% of the
hepatic content [30]. Furthermore, biopsy reports have shown
that fat content is lost towards the more advanced stages of
NAFLD, with the resultant ﬁbrotic tissue being undetectable on
USS [30]. The lack of markers of insulin sensitivity and lipid pro-
ﬁle in the study meant we were unable to non-invasively quan-
tify hepatic fat [31], and hence potentially determine the
numbers of undetected NAFLD on USS within the ‘unexplained’
group.
Our ﬁndings have important clinical and public health impli-
cations. This study raises awareness that NAFLD accounts for a
signiﬁcant proportion of incidental ALFTS commonly encoun-
tered by PCPs, in the absence of a clinical suspicion of liver dis-
ease. We have identiﬁed a potential sub-set of NAFLD patients
with advanced ﬁbrosis (7.6%) that require early assessment and
management in secondary care. We would advocate a certain
degree of reassurance with regard to the absence of underlying
advanced ﬁbrosis/cirrhosis and an impetus for regular metabolic
disease risk assessment and lifestyle modiﬁcations in patients
with a low NFS (57.2%). In the absence of validated scoring
systems, patients at present with an indeterminate NFS require
closer surveillance in primary care with referral to secondary care
as deemed appropriate by the PCP.
In conclusion, we provide novel information on the severity of
NAFLD in a primary care setting, as well as guidance on the triag-
ing of such patients for further investigation and management.Conﬂict of interest
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